Новые данные об использовании комбинированного препарата будесонида/формотерола в терапии хронической обструктивной болезни легких: обзор публикаций 2009 г.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung, and Blood Institute, April 2001 (revised 2008). Accessed at http://www.goldcopd.org.
2. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
3. Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–68.
4. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
5. Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: An assessment of current therapies. Amer J Med 2007; 120: S4–S13.
6. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451–62.
7. Rennard SI, Anderson W, ZuWallack R et al. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087–92.
8. Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
9. Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–69.
10. Tashkin DP, Celli B, Senn S et al. For the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
11. Decramer M, Celli B, Kesten S et al. For the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
12. Celli B, Decramer M, Kesten S et al. Mortality in the 4 Year Trial of Tiotropium (UPLIFT) in Patients with COPD. Am J Respir Crit Care Med 2009 Sep 3. Epub ahead of print.
13. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–53.
14. Pauwels RA, Lo..fdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948–53.
15. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–9.
16. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303.
17. Lo..fdahl CG, Postma DS, Pride NB et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 2007; 29: 1115–9.
18. Cazzola M, Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest 2004; 126: 220–37.
19. Hanania NA. The impact of inhaled corticosteroid and long-acting β-agonist combination therapy on outcomes in COPD. Pulmon Pharmacol Ther 2008; 21: 540–50.
20. Welte T. Optimising treatment for COPD – new strategies for combination therapy. Int J Clin Pract 2009; 63: 1136–49.
21. Calverley P, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
22. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur Respir J 2003; 21: 74–81.
23. Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–19.
24. Halpin DMG. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract, October 2005; 59: 1187–94.
25. Partridge MR, Schuermann W, Beckman O et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1–11.
26. Welte T, Miravitlles M, Hernandez P et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med 2009; 180: 741–50.
27. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712–19.
28. Sta..llberg B, Selroos O, Vogelmeier C et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Research 2009, 10:11 doi:10.1186/1465–9921–10–11.
29. McCarley C, Hanneman SK, Padhye N, Smolensky MH. A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs 2007; 9: 8–20.
30. van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509–17.
31. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043–8.
32. Partridge MR, Karlsson N. Patient insights on the impact of morning symptoms of COPD. P11. Presented at the Sixth International Multidisciplinary Conference on COPD (COPD6), 11–13 June 2008, Birmingham, UK.
33. Miravitlles M, Anzueto A, Legnani D et al. Patient's perception of exacerbations of COPD – the PERCEIVE study. Respir Med 2007; 101: 453–60.
34. Williams V, Bruton A, Ellis-Hill C, McPherson K. What really matters to patients living with chronic obstructive pulmonary disease? An exploratory study. Chron Respir Dis 2007; 4: 77–85.
35. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831–8.
36. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007; 12: 732–9.
37. Partridge M, Karlsson N, Stahl E. Development of the Morning Activities and Symptoms Questionnaire (MASQ) for COPD. Eur Respir J 2008; 32: 814s.
38. Cazzola M, Ando F, Santus P et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20: 556–61.
39. Aaron SD, Vandemheen KL, Fergusson D et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545–55.
40. Singh D, Brooks J, Hagan G et al. Superiority of «triple» therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592–8.
41. Perng DW, Wu CC, Su KC et al. Additive benefits of tiotropium in COPD patients treated with long-acting β-agonists and corticosteroids. Respirology 2006; 11: 598–602.
42. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13: 349–55.
43. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20: 14–9.
44. Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive lung disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med 2002; 30: 1610–5.
45. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82.
46. Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н., Чучалин А.Г. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2009; 2: 33–41.
47. Merino-Sa´nchez M, Alfageme-Michavila I, Lima-A´lvarez J. Prognosis in Patients With Pneumonia and Chronic Obstructive Pulmonary Disease Arch Bronconeumol 2005; 41: 607–11.
48. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with communityacquired pneumonia. Eur Respir J 2006; 28: 346–51.
49. Ruiz de On~a JM, Go´mez M, Celdra´n J, Puente-Maestu L. Neumoni´a en el paciente con enfermedad pulmonar obstructiva cro´nica. Niveles de gravedad y clases de riesgo. Arch Bronconeumol 2003; 39: 101–5.
50. Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407–16.
51. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219–9.
52. Crim C, Calverley PMA, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–7.
53. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–9.
54. Wedzicha JA, Calverley PMA, Seemungal TA et al. For the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
55. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir Med 2008; 102: 1099–108.
56. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–6.
57. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009; 374: 668–70.
58. Esmailpour N, Hogger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol 2000; 122: 151–4.
59. Mortimer KJ, Tattersfi eld AE, Tang Y et al. Plasma concentrations of fl uticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol 2007; 64: 439–44.
60. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21 (Suppl. 41): 46s–53s.
61. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
62. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–7.
63. Celli BR, Barnes PJ. Exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–38.
64. Авдеев С.Н. Небулайзерная терапия суспензией будесонида при обострениях бронхиальной астмы и хронической обструктивной болезни легких. Пульмонология. 2007; 6: 110–8.
65. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (Suppl. 39): 1–34.
66. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest 2006; 130: 1301–11.
67. Maltais F, Ostinelli J, Bourbeau J. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698–703.
68. Авдеев С.Н., Суточникова О.А., Белевский А.С., Чучалин А.Г. Применение небулизированного будесонида при тяжелом обострении хронической обструктивной болезни легких. Рандомизированное контролируемое исследование. Пульмонология. 2003; 5: 81–8.
69. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007; 30: 399–400.
70. Ullman A, Lofdahl CG, Melander B, Svedmyr N. Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy 1996; 51: 745–8.
71. Cazzola M, Di Perna F, D'Amato M et al. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 2001; 95: 917–21.
72. Cazzola M, D'Amato M, Califano C et al. Formoterol as dry powder oral inhalation in comparison with salbutamol metered dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2002; 24: 595–604.
73. Cazzola M, Santus P, Matera MG et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 2003; 97: 458–62.
74. van den Broek KM, Wielders PLM, Creemers JPH, Smeenk FWJ. Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir Med 2008; 102: 579–85.
75. Cazzola M, Salzillo A, De Giglio C et al. Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD. Eur Respir J 2003; 22 (Suppl. 45): 395s.
76. Cazzola M, Salzillo A, Noschese P et al. Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbation of COPD. Eur Respir J 2004; 24 (suppl. 48): 252s.
77. Cazzola M. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19: 79–89.